Conjugation of universal, functionally de-targeted OneAAVTM capsid provides on-demand specificity and scalabilityto address ...
Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ...
The Daily Galaxy on MSN
FDA approves first-ever gene therapy for deafness and 80 percent of kids could hear within a year
Travis used to sleep through everything. Then his mother laughed in the car and woke him up, the first time he had ever heard ...
The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...
As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing and quality control services. SHIRLEY, NY, UNITED ...
Health and Me on MSN
US FDA approves 1st-ever gene therapy for treatment of genetic hearing loss
Developed by American Biotechnology company Regeneron, Otarmeni has been approved for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results